Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

News Opinion Editor's Corner AHA 2025

What’s Going to Be Hot at AHA 2025?

Michael O'Riordan

November 05, 2025

Presentation TCT 2024

TCT 319: Coronary Rotational Atherectomy Elective vs. Bailout in Patients With Severely Calcified Lesions and Chronic Renal Failure Trial

Presenter: Borja Rivero-Santana

October 28, 2024

News Daily News

AHA Urges More Home-Based Dialysis in Advanced Kidney Failure

Michael O'Riordan

August 18, 2022

News Daily News

Higher Subclinical Atherosclerosis in Black Americans Remains Unexplained

Yael L. Maxwell

July 15, 2022

News Daily News

William R. Hiatt, Giant of Vascular Medicine, Dies at 70

L.A. McKeown

December 11, 2020

News Daily News

In CAD, No Long-term Safety Signal for Paclitaxel DCBs: Meta-analysis

L.A. McKeown

March 09, 2020

News Conference News AHA 2015

RIVER-PCI Subanalysis: No Impact of Ranolazine on Quality of Life

L.A. McKeown

November 09, 2015

News Conference News AHA 2015

AHA 2015 Promises Appropriate PCI, Ticagrelor Tolerance, Outcomes With IVUS, and More

Shelley Wood

November 05, 2015

News Conference News TCT 2015

RIVER-PCI: No Advantage to Ranolazine in Patients With Incomplete Revascularization

Yael L. Maxwell

October 13, 2015

News Industry News

Medical Therapy With Ranolazine Did Not Reduce Adverse Events In Patients With Persistent Untreated Heart Artery Blockages After Percutaneous Coronary Intervention

October 13, 2015

News Industry News

Advertisement

What’s Going to Be Hot at AHA 2025?

TCT 319: Coronary Rotational Atherectomy Elective vs. Bailout in Patients With Severely Calcified Lesions and Chronic Renal Failure Trial

AHA Urges More Home-Based Dialysis in Advanced Kidney Failure

Higher Subclinical Atherosclerosis in Black Americans Remains Unexplained

William R. Hiatt, Giant of Vascular Medicine, Dies at 70

In CAD, No Long-term Safety Signal for Paclitaxel DCBs: Meta-analysis

RIVER-PCI Subanalysis: No Impact of Ranolazine on Quality of Life

AHA 2015 Promises Appropriate PCI, Ticagrelor Tolerance, Outcomes With IVUS, and More

RIVER-PCI: No Advantage to Ranolazine in Patients With Incomplete Revascularization

Medical Therapy With Ranolazine Did Not Reduce Adverse Events In Patients With Persistent Untreated Heart Artery Blockages After Percutaneous Coronary Intervention

Medtronic Drug-Coated Balloon (DCB) Demonstrates Consistent Results in Two New Analyses of Complex PAD Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content